Table 2.
Individual characteristics of the COVID-19 recovered subjects.
| Subject number | Age | Gender (Male,M Female,F) | Days Post PCR Diagnosis | SARS CoV-2 RBD specific Immunoglobulin titersa |
SARS Cov-2 whole Virus specific IgG ELISA valuesb | Neutralization titer (FRNT-mNG50)c | ||
|---|---|---|---|---|---|---|---|---|
| IgG | IgM | IgA | ||||||
| 1 | 23 | M | 84 | 2220 | 565 | 220 | 26 | 39 |
| 2 | 22 | F | 84 | 354 | 283 | <100 | 3 | 26 |
| 3 | 68 | M | 40 | 464 | <100 | <100 | 19 | <20 |
| 4 | 35 | M | 51 | 4547 | 393 | 545 | 6 | 113 |
| 5 | 50 | M | 37 | 1354 | 301 | 275 | 7 | 81 |
| 6 | 29 | M | 34 | <100 | 866 | <100 | <1.5 | <20 |
| 7 | 27 | M | 34 | 422 | 104 | 450 | <1.5 | <20 |
| 8 | 25 | M | 34 | 222 | 1031 | <100 | 26 | <20 |
| 9 | 21 | M | 40 | 650 | 588 | 153 | 9 | 25 |
| 10 | 39 | M | 38 | 612 | 539 | 5686 | 12 | 23 |
| 11 | 46 | M | 38 | 2011 | 325 | 224 | 24 | 55 |
| 12 | 31 | M | 38 | 494 | 828 | 183 | 10 | <20 |
| 13 | 20 | M | 41 | 944 | 274 | <100 | 14 | 49 |
| 14 | 36 | M | 41 | 228 | 279 | 1614 | <1.5 | <20 |
| 15 | 34 | M | 44 | 282 | 302 | <100 | 4 | <20 |
| 16 | 70 | M | 44 | 1250 | 220 | 518 | 14 | 43 |
| 17 | 40 | M | 45 | 464 | 112 | 101 | 16 | <20 |
| 18 | 32 | M | 41 | 867 | 381 | 399 | <1.5 | <20 |
| 19 | 57 | M | 45 | 1069 | 354 | 231 | <1.5 | <20 |
| 20 | 27 | F | 49 | 1935 | 528 | <100 | 23 | 80 |
| 21 | 36 | M | 49 | 3156 | 355 | 593 | 28 | 166 |
| 22 | 24 | M | 45 | <100 | 387 | <100 | <1.5 | <20 |
| 23 | 55 | F | 45 | <100 | 778 | <100 | <1.5 | <20 |
| 24 | 15 | M | 45 | 212 | 496 | <100 | <1.5 | <20 |
| 25 | 49 | M | 45 | 4183 | 2958 | 397 | 17 | 657 |
| 26 | 26 | M | 48 | 2352 | <100 | <100 | 16 | 48 |
| 27 | 54 | F | 54 | 1202 | <100 | 182 | 15 | 49 |
| 28 | 53 | M | 52 | 799 | 197 | 417 | 12 | <20 |
| 29 | 52 | M | 48 | 2611 | 249 | 157 | 23 | 46 |
| 30 | 45 | M | 62 | 1490 | 401 | <100 | 15 | 50 |
| 31 | 52 | M | 56 | 10,127 | 421 | 437 | 21 | 434 |
| 32 | 26 | M | 47 | <100 | <100 | <100 | <1.5 | <20 |
| 33 | 32 | M | 57 | 701 | 177 | <100 | 14 | <20 |
| 34 | 44 | M | 49 | 815 | 428 | <100 | 20 | <20 |
| 35 | 32 | M | 40 | 829 | 140 | <100 | 6 | 29 |
| 36 | 44 | M | 42 | 4685 | 494 | 295 | 26 | 167 |
| 37 | 22 | M | 77 | 3954 | 764 | 690 | 24 | 209 |
| 38 | 49 | M | 25 | 24,484 | 2828 | 459 | 22 | 682 |
| 39 | 55 | M | 51 | 371 | 753 | <100 | 17 | <20 |
| 40 | 36 | M | 51 | 621 | 350 | 104 | 17 | <20 |
| 41 | 60 | M | 51 | 156 | 459 | <100 | 17 | 34 |
| 42 | 62 | M | 47 | 467 | 354 | <100 | 6 | <20 |
ELISA end point titre limit of detection is 100.
ELISA was performed with a commercial kit (Covid Kavach, Zydus) using 1:100 dilution of plasma as per by the manufacturer's recommendation. Assay cut off is 1.5.
Neutralization titres: Neutralization assay were performed using 3 fold dilution of plasma, starting at 1:20 up to 1:43,740. Limit of detection for FRNT-mNG50 is 20.